|Bid||37.01 x 800|
|Ask||39.49 x 800|
|Day's Range||35.72 - 39.61|
|52 Week Range||33.19 - 49.89|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CAMBRIDGE, Mass., July 20, 2020 -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging.
Yahoo Finance's On the Move panel discuss the latest headline making news stories.
Shares of Relay Therapeutics Inc. sprinted out of the gate Thursday, after the clinical-stage oncology company's upsized initial public offering priced above the expected range. The first trade was at $35.00 at 11:59 a.m. Eastern for 1.5 million shares, or 75% above the $20 IPO price. On Wednesday, the company said said it was selling 20 million shares in the IPO, which was expected price between $18 and $19 a share, compared with previous plans to sell 14.7 million shares at between $16 to $18 a share. At the IPO price, the company raised $400 million and was valued at $1.74 billion. The company went public at a time that the Renaissance IPO ETF has run up 48.5% over the past three months, while the S&P 500 has advanced 114.5%.